Miracor receives $3.5 million cash infusion to begin pivotal clinical “RAMSES” trial of its PICSO system, designed to improve myocardial perfusion following primary PCI
“One in three heart attack patients has impaired blood flow even after coronary angioplasty, increasing the risk of death within one year by almost 300 percent. PICSO is designed to help these at-risk patients.”
Jon H. Hoem, CEO, Miracor Medical Systems
VIENNA, Austria, Feb. 28, 2012—Miracor Medical Systems GmbH announced today that it has received a cash infusion of $3.5 million (€2.6 million) in the form of a research grant and loan from the Austrian Research Promotion Agency (“FFG”), the national funding institution for applied research and development in Austria.
The funding will be used primarily to commence the pivotal clinical trial—RAMSES—of the Company’s PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) system (click here for the 2 minutes animation of the PICSO technology). The RAMSES trial is designed to understand how PICSO can help acute coronary syndrome patients with large anterior infarcts having ECG changes with poor microcirculation after revascularization.
In a feasibility study of stable angina patients, the PICSO procedure was performed successfully in 10 patients by Prof. Dr. med. Jan Piek and his group at the Academic Medical Center, Amsterdam, The Netherlands. Based on these outstanding clinical results and the availability of fresh capital, Miracor will soon initiate the pivotal ‘RAMSES’ study in acute coronary syndrome patients.
“Despite a successful primary PCI, suboptimal myocardial reperfusion still occurs in about 30 percent of STEMI patients, and this high incidence is strongly linked to unfavorable outcomes for patients,” said Jon H. Hoem, Miracor CEO. “Our feasibility study demonstrated that PICSO clearly reduces ischemia acutely when an infarct was induced in stable angina patients, which is why we are delighted to have this new funding from FFG supporting the RAMSES pivotal clinical trial in STEMI patients,” added Hoem.
About PISCO® and cardioprotected PCI (cPCITM)
About Miracor Medical Systems GmbH